The class of BVES Inhibitors comprises a range of chemical compounds that indirectly inhibit the activity or influence of the Blood Vessel Epicardial Substance protein through various signaling pathways and cellular processes. These inhibitors target different aspects of cellular signaling and function, which are interconnected with the roles and effects of BVES in cells. For instance, inhibitors of the Wnt and Hedgehog pathways impact cellular differentiation and migration, processes where BVES has a significant role. Similarly, compounds like GSK-3β, PI3K, and Akt inhibitors affect downstream effects of these pathways, thereby indirectly modulating the activity related to BVES.
These inhibitors are not specific to BVES but influence the protein's function by altering related signaling cascades and cellular mechanisms. This includes modulation of kinase activities, transcription factors, and other signaling molecules like ROCK, MAPK, JNK, and NF-κB. By affecting these pathways, the inhibitors contribute to changes in cellular processes like proliferation, apoptosis, stress responses, and cytoskeletal dynamics, all of which are crucial to the functional context of BVES. Additionally, agents like calcium channel blockers and histone deacetylase inhibitors demonstrate the broad spectrum of mechanisms through which these compounds can indirectly influence BVES activity, emphasizing the complex network of cellular signaling in which BVES is embedded.
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
Inhibits the Wnt/β-catenin signaling pathway by stabilizing Axin, which is involved in the degradation of β-catenin, thus indirectly affecting BVES activity. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
Inhibits GSK-3β, leading to increased β-catenin levels in the Wnt signaling pathway, which interacts with BVES in cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, affecting AKT signaling and thereby influencing pathways associated with BVES, particularly in cell survival and migration. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
Allosteric inhibitor of Akt, modifying downstream signaling of PI3K, which affects cellular processes related to BVES. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Inhibits ROCK, affecting cytoskeletal organization and cellular motility, indirectly impacting BVES-related cellular functions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK in the MAPK/ERK pathway, affecting cell growth and differentiation processes indirectly related to BVES. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, affecting cellular stress responses and apoptosis, thereby indirectly influencing BVES function in stress-related pathways. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Inhibits NF-κB activation, impacting inflammatory response and other cellular processes indirectly related to BVES. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Blocks L-type calcium channels, altering intracellular calcium dynamics, thereby affecting cellular functions associated with BVES. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Inhibits histone deacetylases, affecting gene expression and chromatin structure, thus influencing pathways where BVES is involved. |